Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2021-04-21 Annual Report
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech Holding ASA publishes the Annual Report 2020
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT 2020' for PCI Biotech Holding ASA. It contains a comprehensive overview of the company's business, technology, board report, and references financial statements. It is a full-length annual report, not an announcement or a summary. FY 2020
2021-04-21 English
PCI Biotech Holding ASA publishes the Annual Report 2020
Report Publication Announcement Classification · 100% confidence The document explicitly states: "PCI Biotech Holding ASA publishes the Annual Report 2020" and "The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2020 and the report is attached." Although the title mentions the 'Annual Report 2020', the document itself is a very short announcement (2946 characters) whose primary function is to state that the report has been approved and is attached/available. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating a report is published or attached should be classified as a Report Publication Announcement (RPA), not the full report (10-K).
2021-04-21 English
PCI Biotech to present at European Biotech Investor Days 2021
Regulatory Filings Classification · 100% confidence The document is a short announcement dated April 6, 2021, stating that PCI Biotech will present at the 'European Biotech Investor Days 2021' on April 8, 2021. It provides details about the presentation time, the presenter (CEO), and a link to access the live event. It also mentions that the presentation slides will be made available on the company website after the event. Since the document is short (3348 chars) and primarily announces the *upcoming* presentation/participation in an investor event rather than being the presentation itself or a formal regulatory filing like a 10-K or ER, it fits best under the category of Investor Presentation (IP) or, given the context of announcing participation in an investor conference, it could be related to investor relations activities. However, none of the definitions perfectly capture an announcement of participation in a third-party investor conference. The closest fit among the options that relates to investor communication about company status is Investor Presentation (IP), although this document is an announcement *about* a presentation, not the presentation slides themselves. Given the options, and recognizing this is a standard corporate communication about engaging with investors, it is most closely related to investor-facing materials. If the document were the actual slides, it would be IP. Since it's an announcement about an event where they will present, and it's not a standard regulatory filing, it is often categorized as a general Investor Relations announcement. Since 'Investor Presentation' (IP) is available, and the core activity is presenting company information to investors, I will select IP, acknowledging it's an announcement *of* a presentation. Alternatively, if it were purely a notice of an event without substantive company info, RNS might apply. Given the context of biotech investor days, IP is the most relevant category for the subject matter being discussed.
2021-04-06 English
PCI Biotech fourth quarter and preliminary full year 2020 results
Investor Presentation Classification · 98% confidence The document is titled 'Q4 & Interim Full Year 2020 PRESENTATION' and contains detailed slides covering a review of 2020, updates on specific programs (fimaCHEM, fimaVACC, fimaNAC), clinical trial progress (RELEASE study), and future timelines. The content is highly structured, visual, and clearly intended for an investor audience to review performance and strategy. This format strongly indicates an Investor Presentation (IP). Although it covers Q4 and Full Year results, the format is a presentation, not the formal regulatory report (like 10-K or IR). The mention of a 'teleconference' for Q&A further supports the presentation/investor call context.
2021-02-24 English
PCI Biotech fourth quarter and preliminary full year 2020 results
Earnings Release Classification · 99% confidence The document explicitly states it is the "FOURTH QUARTER AND PRELIMINARY FULL YEAR REPORT 2020". It contains detailed financial tables comparing Q4 2020 vs Q4 2019 and FY 2020 vs FY 2019, including operating results, comprehensive income, and cash flow. It also includes an operational review, highlights of development programs (fimaCHEM, fimaVACC, fimaNAC), and management commentary on the year's performance. This structure is characteristic of a comprehensive annual financial report, which aligns with the definition of a 10-K (Annual Report), even though the text might be an excerpt or preliminary version released before the final 10-K filing. Given the comprehensive nature covering the full fiscal year and detailed financials, 10-K is the most appropriate classification over a simple Earnings Release (ER) or Interim Report (IR). Q4 2020
2021-02-24 English
PCI Biotech fourth quarter and preliminary full year 2020 results
Earnings Release Classification · 100% confidence The document explicitly states it announces the 'PCI Biotech fourth quarter and preliminary full year 2020 results' and mentions that the 'interim Q4 and preliminary full year 2020 results' are being announced. It also details that the 'interim report and the presentation will also be available' and schedules a 'Q&A session' via webcast/teleconference, which is characteristic of an earnings announcement. Since it covers quarterly results and provides highlights, it fits the definition of an Earnings Release (ER). Although it mentions an 'interim report' is enclosed, the primary function of this document is the announcement of the results and the scheduling of the call, making ER the most appropriate primary classification over IR (Interim Report) or RPA (Report Publication Announcement), especially given the context of quarterly results. Q4 2020
2021-02-24 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.